Search
VT-111
go.drugbank.com/drugs/DB05646InvestigationalVT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.
MIV-701
go.drugbank.com/drugs/DB05736ExperimentalMIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Roxarsone
go.drugbank.com/drugs/DB11458ExperimentalVet approvedRoxarsone is an organoarsenic molecule added to poultry feed.
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalAVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.
Ertiprotafib
go.drugbank.com/drugs/DB06521ExperimentalIn insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.
Inhibitor of P38 Kinase
go.drugbank.com/drugs/DB01953ExperimentalThese are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. This drug is known to target mitogen-activated protein kinase 14.
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalBrasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.
5-(5-(4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole
go.drugbank.com/drugs/DB08724ExperimentalThese are aromatic compounds containing an ether group substituted with a benzene ring. This medication is known to target genome polyprotein.
Fluciclatide
go.drugbank.com/drugs/DB14842InvestigationalFluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.